Comments
Loading...

Alterity Therapeutics Analyst Ratings

PRNAFOTCPK
Logo brought to you by Benzinga Data
$0.0101
At close: Jan 21, 10:46 AM EDT

Alterity Therapeutics Analyst Ratings and Price Targets | OTC:PRNAF | Benzinga

Alterity Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Alterity Therapeutics Corp from these most-recent analyst ratings.

Analyst Ratings for Alterity Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Alterity Therapeutics (PRNAF) stock?

A

There is no price target for Alterity Therapeutics

Q

What is the most recent analyst rating for Alterity Therapeutics (PRNAF)?

A

There is no analyst for Alterity Therapeutics

Q

When was the last upgrade for Alterity Therapeutics (PRNAF)?

A

There is no last upgrade for Alterity Therapeutics

Q

When was the last downgrade for Alterity Therapeutics (PRNAF)?

A

There is no last downgrade for Alterity Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Alterity Therapeutics (PRNAF)?

A

There is no next analyst rating for Alterity Therapeutics.

Q

Is the Analyst Rating Alterity Therapeutics (PRNAF) correct?

A

There is no next analyst rating for Alterity Therapeutics.

Browse analyst ratings and price targets on all stocks.